For research use only. Not for therapeutic Use.
Rulonilimab（Cat No.:I042077）is an investigational monoclonal antibody designed to target and block the immune checkpoint receptor LAG-3 (Lymphocyte Activation Gene-3). LAG-3 is involved in the suppression of immune responses, particularly in the tumor microenvironment, allowing cancer cells to evade immune detection. By inhibiting LAG-3, rulonilimab aims to enhance T-cell activation and improve the body’s immune response against tumors. It is being evaluated in clinical trials for various cancers, including melanoma and non-small cell lung cancer (NSCLC), to assess its safety, efficacy, and potential as part of combination immunotherapy treatments.
| CAS Number | 2417124-95-7 |
| Purity | ≥95% |
